An Early Phase 1 interventional study of CAR-T cell infusion in Relapsed Acute Lymphoblastic Leukemia (ALL), sponsored by Dr. Zaineb Akram. Recruiting at 1 site in Pakistan. Open to participants aged 5 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Dr. Zaineb Akram · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 6 open to participants now, 8 under way, none of them phase 3. Chimeric Antigen Receptor T-cells · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 1, and was the 10th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →6 of the 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 2 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Shenzhen University General Hospital · Sites in China
Ages 18–75
The Affiliated Hospital of Xuzhou Medical University · Sites in China
Ages 18–70
Zhejiang University · Sites in China
Ages 3–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 5 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3
First in 2016; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 19 across the 10 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
Dr. Zaineb Akram is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Dr. Zaineb Akram has 1 study filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and the second most frequent acute leukemia in adults. B-cell ALL constitutes approximately 85% of all ALL diagnoses. In Pakistan, ALL represents the most prevalent haematological malignancy presenting to tertiary centres, with AFBMTC receiving the largest national referral volume for haematological malignancies and transplantation.
First-line combination chemotherapy achieves complete remission (CR) in >95% of paediatric patients; however, 15-20% relapse. Outcomes following first relapse are substantially inferior: second-line salvage chemotherapy achieves CR2 in 30-50% of patients, and long-term event-free survival (EFS) after conventional chemotherapy alone is \<10%. Outcomes in adult ALL are even more dismal, with OS at 5 years below 40% even in first CR without allogeneic transplant.
Patients with primary refractory ALL or multiply relapsed ALL have an unmet medical need for novel therapeutic approaches. The classical paradigm of chemotherapy followed by allogeneic haematopoietic stem cell transplantation (allo-HSCT) is limited by donor availability, conditioning-related mortality, and inability to achieve remission before transplant.
1.2 CD19 as a Therapeutic Target CD19 is a B-lineage surface glycoprotein expressed on the majority of B-cell ALL blasts, retained through disease evolution, and absent on haematopoietic stem cells, non-haematopoietic tissues, and most normal tissues. CD19 expression is confirmed in >95% of B-ALL cases, making it the optimal target for immunotherapy. The only significant on-target off-tumour consequence is B-cell aplasia and hypogammaglobulinaemia, which are clinically manageable with immunoglobulin replacement.
1.3 CAR-T Cell Therapy: Scientific and Clinical Rationale Chimeric antigen receptor T-cell (CAR-T) therapy involves ex vivo genetic modification of autologous T cells to express a synthetic receptor comprising: (1) an extracellular antigen-binding domain (anti-CD19 scFv), (2) a hinge and transmembrane domain, (3) an intracellular costimulatory domain (4-1BB/CD137), and (4) a CD3ζ signalling domain. Upon infusion, CAR-T cells recognise CD19+ target cells in an MHC-independent manner, inducing direct cytotoxicity, cytokine release, and in vivo proliferation.
The 4-1BB costimulatory domain (used in this protocol) confers superior persistence and memory formation compared to CD28-based constructs, as demonstrated in seminal studies from the University of Pennsylvania and subsequently confirmed in the ELIANA global Phase II trial of tisagenlecleucel (Maude et al., NEJM 2018), which demonstrated an overall remission rate of 81% and 12-month EFS of 50% in heavily pre-treated paediatric and young adult r/r B-ALL.
1.4 Institutional Rationale and LMIC Context AFBMTC is Pakistan's first and largest haematology and cellular therapy centre, established in 2001 under NUMS, with a cumulative experience of >2,000 allogeneic, autologous, and haploidentical HSCTs. AFBMTC possesses critical institutional infrastructure for CAR-T implementation including GMP-equivalent cleanroom facilities, validated cryopreservation and leukapheresis capabilities, and an established mesenchymal stromal cell (MSC) GMP program with over a decade of experience - directly translatable to CAR-T manufacturing quality standards.
Access to commercially approved CAR-T products (tisagenlecleucel, axicabtagene ciloleucel) is prohibitively expensive and effectively unavailable in Pakistan. AFBMTC's model of on-site CAR-T manufacturing using an internationally validated lentiviral vector platform (BIOCCUS, China) and automated closed-system bioreactor technology (CELLBRI) - analogous to the NexCAR19 program (ImmunoACT/IIT Bombay, India) in the LMIC context - provides a feasible, cost-recoverable, and sustainable approach to making this therapy accessible. This pilot study represents Pakistan's first academic CAR-T trial and aims to demonstrate manufacturing feasibility, safety, and early efficacy to support future regulatory approval and programme scale-up.
1.5 Investigational Product Description
The investigational product is autologous anti-CD19 CAR-T cells generated from patient-derived peripheral blood T cells using:
Inclusion Criteria:
All of the following criteria must be met for enrolment:
2. Morphologically or immunophenotypically confirmed B-cell ALL (CD19+) meeting one or more of the following criteria:
5. Adequate organ function at screening:
Patients meeting ANY of the following criteria will be excluded:
17. Prohibited concomitant medications at time of CAR-T infusion (detailed in Section 6.5):
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5.1 Leukapheresis Leukapheresis will be performed at AFBMTC using standard large-volume apheresis technique on a validated apheresis platform. Non-mobilised peripheral blood mononuclear cells (PBMCs) will be collected targeting ≥1 × 10⁸ CD3+ T cells/kg (paediatric) or a minimum of 5 × 10⁸ CD3+ T cells total (adult). Pre-apheresis ALC and CD3+ count must both exceed 100/µL. Leukapheresis products will be processed immediately for manufacturing or cryopreserved in validated storage at AFBMTC. 5.2 CAR-T Cell Manufacturing 5.2.1 Vector Platform The anti-CD19 CAR transgene will be delivered using a replication-deficient, self-inactivating (SIN) third-generation lentiviral vector supplied by BIOCCUS (China). The vector encodes: anti-CD19 scFv (murine or humanised) - CD8α hinge/transmembrane domain - 4-1BB costimulatory domain - CD3ζ activation domain. The lentiviral vector backbone incorporates safety modifications including deletion of viral enhancer elements in the 3' LTR (self-inactivati
Biological: CAR-T cell infusion
CAR-T Cell infusion therapy will be given
To evaluate the safety and feasibility of autologous anti-CD19 CAR-T cell therapy manufactured at AFBMTC using the BIOCCUS lentiviral vector and CELLBRI automated expansion system in patients aged 5-50 years with relapsed or refractory B-cell ALL.
Primary Safety Incidence/grade of CRS (ASTCT) Day 0-28
Time frame: 1 year after infusion of CAR-T
Plan to share: Yes — IPD will be shared after enrollment is complete and upon request by email
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: 31 December 2027 to 31 December 2028
Access criteria: IPD will be made available upon request through email
Data sharing details ↗ · nibmtevents.com
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 18 months is below that.
Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chimeric Antigen Receptor T-cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Dr. Zaineb Akram